Sign In
Buy KROS
$11.15
+0.500 (+4.69%)
At Close: Aug 07, 2026
Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update
12:00pm, Tuesday, 04'th Aug 2020
LEXINGTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, dev
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation
02:12pm, Wednesday, 29'th Jul 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Keros Therapeutics Set to Join Russell 2000® Index
11:01am, Friday, 26'th Jun 2020
Keros Therapeutics, Inc. (“Keros” or the “Company”) (KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patie
Keros Therapeutics (KROS) in Focus: Stock Moves 6.8% Higher
12:34pm, Wednesday, 24'th Jun 2020
Keros Therapeutics (KROS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Poster presentations introduce data demonstrating KER-050 robustly promoted hematopoiesis in multiple animal species in preclinical studies and support a potentially novel mechanism of action. Oral p
Keros Therapeutics To Present At The Jefferies 2020 Virtual Healthcare Conference
11:01am, Thursday, 28'th May 2020
Keros Therapeutics, Inc. (“Keros”) (KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from he
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
11:00am, Friday, 22'nd May 2020
LEXINGTON, Mass., May 22, 2020 -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and.
Keros Therapeutics to Present at the Virtual 25th Annual Congress of the European Hematology Association
01:15pm, Thursday, 14'th May 2020
Keros Therapeutics, Inc. (“Keros”) (KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from he
3 Biotech Stocks With Plenty of Upside in the Pipeline
03:46pm, Tuesday, 05'th May 2020
A sense of cautious optimism is looming over the Street given the progress in the reopening of the U.S. economy, and while the recent uptick isn’t necessarily indicative of a full recovery, it’s c
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1
11:19am, Thursday, 30'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)• Arvinas Inc (NASDAQ: ARVN) • Biondvax Pharmaceu
The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update
11:36am, Tuesday, 28'th Apr 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) * AstraZeneca plc (NYSE: AZN) * Alnylam Pharmaceuti
Kerr Mines Plans First Phase of 2020 Drilling Program at Copperstone | INN
07:06pm, Thursday, 23'rd Apr 2020
Kerr Mines Inc. (TSX:KER) announces its plans for the first phase of its 2020 resource and reserve expansion program at the Copperstone Mine
These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys?
10:39am, Thursday, 23'rd Apr 2020
These companies just raised significant cash to advance promising drug pipelines.
